Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study
about
Pharmacological treatment for memory disorder in multiple sclerosisAlzheimer's Disease: Exploring the Role of Inflammation and Implications for TreatmentAn update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerationsEfficacy and side effects of natalizumab therapy in patients with multiple sclerosis.Improved working ability in a contemporary MS population compared with a historic non-treated MS population in the same geographic area of Sweden.Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life settingThe representation of inflammatory signals in the brain - a model for subjective fatigue in multiple sclerosis.Routes of administration and dose optimization of soluble antigen arrays in mice with experimental autoimmune encephalomyelitis.Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time SleepinessImpact of natalizumab treatment on fatigue, mood, and aspects of cognition in relapsing-remitting multiple sclerosisNatalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.The use of immune modulating drugs for the treatment of multiple sclerosis.Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life.Work-related problems in multiple sclerosis: a literature review on its associates and determinants.Immunomodulatory treatments and cognition in MS.Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients.Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle.NAPS-MS: Natalizumab Effects on Parameters of Sleep in Patients with Multiple Sclerosis.Cognitive functioning following one-year natalizumab treatment: A non-randomized clinical trial.White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis-A Longitudinal Observational Study.Fatigue as a symptom or comorbidity of neurological diseases.Is there a link between inflammation and fatigue in multiple sclerosis?Computer-assisted rehabilitation of attention in pediatric multiple sclerosis and ADHD patients: a pilot trial.The still under-investigated role of cognitive deficits in PML diagnosis
P2860
Q24201735-AD4972E6-5AD8-465C-BB6E-456DA0C26418Q26776157-0296CF41-8FBB-43B5-8E40-C2A69DC3166AQ27009769-AF318CEF-7738-4C29-ADAC-5473263A8600Q33573208-6C3E3F80-1385-44FF-AF8E-DAD31140DEFFQ33693081-D5FBB188-EF7D-4280-B9CA-9AFC39430483Q34650470-A090B083-8969-47F2-A213-0184AF8B30DAQ34677503-D31E77CB-1FCC-40C4-811C-08774D377DA5Q35032669-C01C9927-9F40-439D-A92E-7BC7EACA0DCCQ35110437-715B678B-65B3-4F88-8001-71146475FAACQ35591351-F9A0ECA1-22FA-4325-BC01-2DEF0B87A950Q35684256-92B7D797-30E4-4B02-89DA-CA1A9E4DD1DEQ36975701-542AE79E-37FD-4780-98E5-94FFAF76C056Q37577290-7DB77F00-CCB8-4859-B704-03C62A0B078AQ37696989-D4EE9D67-FC48-4176-8390-17C5A427452BQ38554887-EFACEF42-236A-4432-9173-4E669F562985Q38942635-D08E6154-86DC-423E-9C6B-4824C654BC5FQ39711019-10DBFB82-FCE5-4DC5-A4AE-849E2C40AE4EQ41809315-4AEF8AA1-F8AA-4542-8729-C0DA3F8356FFQ42356708-23A36FA2-337D-4946-9432-67C1F40828BCQ47697833-D9D923EE-117B-4CA1-96A6-B901212E1F0CQ48845593-ED90E7A8-A1A4-4D9B-8999-C8C2F282AB49Q49539768-20616D86-3961-4542-A078-57A175CD2FEEQ50063088-4CCFD16B-0690-491F-897B-28CBB617E3FEQ55347930-4083E6BF-136D-4BC2-98D5-E25CFD80C55BQ55456081-C5D4CB9C-7842-4E32-9069-499C141BF66EQ58864832-FE9A7720-92AF-4943-8672-8E7C8C52C793
P2860
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study
description
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
article publié dans la revue scientifique PLoS ONE
@fr
artículu científicu espublizáu en 2012
@ast
im Januar 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 2012)
@en
vedecký článok (publikovaný 2012)
@sk
vědecký článek publikovaný v roce 2012
@cs
wetenschappelijk artikel (gepubliceerd in 2012)
@nl
наукова стаття, опублікована у 2012
@uk
name
Impact of natalizumab on cogni ...... two years observational study
@ast
Impact of natalizumab on cogni ...... two years observational study
@en
Impact of natalizumab on cogni ...... two years observational study
@nl
type
label
Impact of natalizumab on cogni ...... two years observational study
@ast
Impact of natalizumab on cogni ...... two years observational study
@en
Impact of natalizumab on cogni ...... two years observational study
@nl
prefLabel
Impact of natalizumab on cogni ...... two years observational study
@ast
Impact of natalizumab on cogni ...... two years observational study
@en
Impact of natalizumab on cogni ...... two years observational study
@nl
P2093
P2860
P50
P1433
P1476
Impact of natalizumab on cogni ...... two years observational study
@en
P2093
Benedetta Goretti
Damiano Paolicelli
Emilio Portaccio
Mariangela D'Onghia
Pietro Iaffaldano
Rosa Gemma Viterbo
Stefano Zoccolella
Vita Direnzo
P2860
P304
P356
10.1371/JOURNAL.PONE.0035843
P407
P577
2012-04-25T00:00:00Z